IL254088A0 - Cure using cd137 binding antibody - Google Patents

Cure using cd137 binding antibody

Info

Publication number
IL254088A0
IL254088A0 IL254088A IL25408817A IL254088A0 IL 254088 A0 IL254088 A0 IL 254088A0 IL 254088 A IL254088 A IL 254088A IL 25408817 A IL25408817 A IL 25408817A IL 254088 A0 IL254088 A0 IL 254088A0
Authority
IL
Israel
Prior art keywords
bind
antibody therapeutics
therapeutics
antibody
Prior art date
Application number
IL254088A
Other languages
English (en)
Hebrew (he)
Inventor
John Dixon Gray
Heyue Zhou
Original Assignee
Sorrento Therapeutics Inc
John Dixon Gray
Heyue Zhou
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sorrento Therapeutics Inc, John Dixon Gray, Heyue Zhou filed Critical Sorrento Therapeutics Inc
Publication of IL254088A0 publication Critical patent/IL254088A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Reproductive Health (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL254088A 2015-02-22 2017-08-21 Cure using cd137 binding antibody IL254088A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562119211P 2015-02-22 2015-02-22
PCT/US2016/018897 WO2016134358A1 (en) 2015-02-22 2016-02-22 Antibody therapeutics that bind cd137

Publications (1)

Publication Number Publication Date
IL254088A0 true IL254088A0 (en) 2017-10-31

Family

ID=56690285

Family Applications (1)

Application Number Title Priority Date Filing Date
IL254088A IL254088A0 (en) 2015-02-22 2017-08-21 Cure using cd137 binding antibody

Country Status (12)

Country Link
US (4) US10233251B2 (enExample)
EP (1) EP3258959A4 (enExample)
JP (1) JP2018508509A (enExample)
KR (1) KR20180016972A (enExample)
CN (1) CN107921104A (enExample)
AR (1) AR105313A1 (enExample)
AU (1) AU2016219772A1 (enExample)
CA (1) CA2977257A1 (enExample)
IL (1) IL254088A0 (enExample)
MX (1) MX2017010793A (enExample)
TW (1) TW201632559A (enExample)
WO (1) WO2016134358A1 (enExample)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201203051D0 (en) * 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
KR101503341B1 (ko) 2014-03-12 2015-03-18 국립암센터 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
US10233251B2 (en) * 2015-02-22 2019-03-19 Sorrento Therapeutics, Inc. Antibody therapeutics that bind CD137
EP3988577A1 (en) * 2015-05-21 2022-04-27 Alligator Bioscience AB Anti-cd137 antibodies
US11214618B2 (en) 2016-06-20 2022-01-04 F-Star Therapeutics Limited LAG-3 binding members
NZ789594A (en) 2016-06-20 2025-07-25 Kymab Ltd Anti-PD-L1 antibodies
CA3030636A1 (en) 2016-07-14 2018-01-18 Genmab A/S Multispecific antibodies against cd40 and cd137
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
GB201619648D0 (en) 2016-11-21 2017-01-04 Alligator Bioscience Ab Novel antibodies and uses thereof
US10899842B2 (en) 2016-11-23 2021-01-26 Immunoah Therapeutics, Inc. 4-1BB binding proteins and uses thereof
EP4032911A1 (en) * 2017-01-06 2022-07-27 Eutilex Co., Ltd. Anti-human 4-1bb antibodies and use thereof
JP6827113B2 (ja) 2017-01-21 2021-02-10 広州白雲山漢方現代薬業有限公司Ｇｕａｎｇｚｈｏｕ Ｈａｎｆａｎｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．，Ｌｔｄ． シェーグレン症候群の治療におけるペオニフロリン−６’−ｏ−ベンゼンスルホン酸の使用
KR102585848B1 (ko) 2017-02-24 2023-10-11 마크로제닉스, 인크. Cd137 및 종양 항원에 결합할 수 있는 이중특이적 결합 분자, 및 그것의 용도
WO2018191502A2 (en) * 2017-04-13 2018-10-18 Agenus Inc. Anti-cd137 antibodies and methods of use thereof
MY202336A (en) 2017-07-11 2024-04-24 Compass Therapeutics Llc Agonist antibodies that bind human cd137 and uses thereof
US11512134B2 (en) 2017-08-01 2022-11-29 Eli Lilly And Company Anti-CD137 antibodies
CN111182919B (zh) 2017-08-01 2023-07-07 伊莱利利公司 抗cd137抗体
MX2020001198A (es) * 2017-08-04 2020-09-07 Genmab As Agentes de union que se unen a ligando 1 de muerte programada (pd-l1) y grupo de diferenciacion 137 (cd137) y uso de los mismos.
CN111511762B (zh) * 2017-08-21 2025-05-06 天演药业公司 抗cd137分子及其用途
AU2018348429B2 (en) * 2017-10-10 2025-08-28 Numab Therapeutics AG Multispecific antibody
WO2019089753A2 (en) 2017-10-31 2019-05-09 Compass Therapeutics Llc Cd137 antibodies and pd-1 antagonists and uses thereof
TWI701259B (zh) * 2017-11-09 2020-08-11 大陸商上海懷越生物科技有限公司 ４﹘１ｂｂ抗體及其製備方法和應用
EP3713961A2 (en) 2017-11-20 2020-09-30 Compass Therapeutics LLC Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
WO2019104716A1 (en) * 2017-12-01 2019-06-06 Adagene Inc. Methods for using cd137 ligand as biomarker for treatment with anti-cd137 antibody
US11548948B2 (en) 2017-12-19 2023-01-10 F-Star Therapeutics Limited FC binding fragments comprising a PD-L1 antigen-binding site
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
MX2020008791A (es) * 2018-02-23 2021-01-08 Bicycletx Ltd Ligandos de peptidos biciclicos multimericos.
MX2020009863A (es) 2018-03-23 2021-01-08 Lilly Co Eli Anticuerpos anti-cd137 para combinacion con anticuerpos anti-pd-l1.
MY202157A (en) * 2018-04-09 2024-04-09 Oricell Therapeutics Co Ltd Anti-pd-l1 antibody and use thereof
EP3797120A1 (en) 2018-05-21 2021-03-31 Compass Therapeutics LLC Compositions and methods for enhancing the killing of target cells by nk cells
WO2020006374A2 (en) * 2018-06-29 2020-01-02 Alector Llc Anti-sirp-beta1 antibodies and methods of use thereof
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
EP3820898B1 (en) 2018-07-12 2025-09-03 invoX Pharma Limited Antibody molecules that bind cd137 and ox40
GB201811404D0 (en) * 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
SG11202100170RA (en) 2018-07-12 2021-02-25 F Star Beta Ltd Antibody molecules that bind pd-l1 and cd137
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
US11939381B2 (en) 2018-07-19 2024-03-26 Eli Lilly And Company Bispecific antibodies targeting immune checkpoints
WO2020023556A1 (en) 2018-07-23 2020-01-30 Magenta Therapeutics, Inc. Use of anti-cd137 antibody drug conjugate (adc) in allogeneic cell therapy
EP3827019A1 (en) 2018-07-24 2021-06-02 Inhibrx, Inc. Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
AU2019340530A1 (en) * 2018-09-12 2021-03-11 Eucure (Beijing) Biopharma Co., Ltd Anti-TNFRSF9 antibodies and uses thereof
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN120623346A (zh) 2018-10-11 2025-09-12 因荷布瑞克斯生物科学公司 Pd-1单结构域抗体及其治疗组合物
JP7611820B2 (ja) 2018-10-11 2025-01-10 インヒブルクス バイオサイエンシズ インコーポレイテッド Ｄｌｌ３シングルドメイン抗体およびその治療用組成物
BR112021010402A2 (pt) * 2018-11-30 2021-08-24 Abl Bio Inc. Anticorpos biespecíficos anti-pd-l1/anti-4-1bb e uso dos mesmos
CA3125451A1 (en) * 2019-01-02 2020-07-09 Qlsf Biotherapeutics Inc. Cd137 agonist antibodies and uses thereof
EP3911682A4 (en) * 2019-01-14 2023-03-15 The Regents of the University of California COMPOSITIONS AND METHODS TO MODULATE CELLULAR INTERNALIZATION
AU2020228367A1 (en) * 2019-02-26 2021-10-14 Vivasor, Inc. Antigen binding proteins that bind BCMA
MX2021012961A (es) 2019-04-24 2021-11-25 Heidelberg Pharma Res Gmbh Conjugados de anticuerpo y farmaco de amatoxina y usos de los mismos.
JP7302028B2 (ja) * 2019-06-04 2023-07-03 アカデミア シニカ 上皮成長因子受容体を標的とするリガンド、及び腫瘍を治療するための組成物
EP3990495A4 (en) 2019-06-26 2023-11-08 AP Biosciences, Inc. ANTIBODIES FOR ACTIVATION OF T CELLS
EP4041772A4 (en) 2019-10-11 2024-04-24 Nanjing Leads Biolabs Co., Ltd. 4-1BB-BINDING ANTIBODIES AND USES THEREOF
EP4100439A4 (en) * 2020-02-05 2024-05-29 The Board Of Regents Of The University Of Texas System NOVEL LILRB2 ANTIBODIES AND USES THEREOF
EP4137155A4 (en) * 2020-04-17 2024-10-30 Shihuida Pharmaceutical Group (Jilin) Co., Ltd. PREPARATION SPECIFICALLY RELATED TO CD137 AND ITS USE
TW202214303A (zh) 2020-05-19 2022-04-16 德商百靈佳殷格翰國際股份有限公司 用於癌症治療之結合分子
CN113842456B (zh) * 2020-06-28 2022-07-26 上海齐鲁制药研究中心有限公司 一种抗人4-1bb的单克隆抗体制剂及其用途
TW202220677A (zh) * 2020-07-31 2022-06-01 日商中外製藥股份有限公司 含有表現嵌合受體之細胞的醫藥組成物
CN116199778B (zh) * 2021-12-01 2025-06-03 上海君实生物医药科技股份有限公司 抗4-1bb抗体及其用途
CN115975032B (zh) * 2022-12-19 2024-06-07 华润生物医药有限公司 一种cldn18.2抗体及其应用
WO2025049858A1 (en) * 2023-09-01 2025-03-06 Amgen Inc. Molecules for treatment of cancer
WO2025189194A1 (en) * 2024-03-08 2025-09-12 Dana-Farber Cancer Institute, Inc. Antibodies against vegf and methods of use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SV2007000775A (es) * 2001-01-05 2007-03-15 Pfizer Anticuerpos contra el receptor del factor de crecimiento similar a insulina
US7651686B2 (en) 2001-10-09 2010-01-26 Mayo Foundation For Medical Education And Research Enhancement of immune responses by 4-1bb-binding agents
US20030223989A1 (en) * 2002-04-18 2003-12-04 Pluenneke John D. CD137 agonists to treat patients with IgE-mediated conditions
US7288638B2 (en) * 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
EP2399935A3 (en) 2005-02-15 2012-02-22 GTC Biotherapeutics, Inc. An anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof
CN105481983B (zh) * 2010-09-09 2021-09-03 辉瑞公司 4-1bb结合分子
TWI629355B (zh) * 2010-11-17 2018-07-11 中外製藥股份有限公司 具有替代血液凝固第ｖｉｉｉ因子之功能的多重專一性抗原結合分子
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
US10233251B2 (en) 2015-02-22 2019-03-19 Sorrento Therapeutics, Inc. Antibody therapeutics that bind CD137
CA2978892A1 (en) 2015-03-06 2016-09-15 Sorrento Therapeutics, Inc. Antibody therapeutics that bind tim3
EP3827019A1 (en) * 2018-07-24 2021-06-02 Inhibrx, Inc. Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
CN120623346A (zh) * 2018-10-11 2025-09-12 因荷布瑞克斯生物科学公司 Pd-1单结构域抗体及其治疗组合物

Also Published As

Publication number Publication date
US20170226215A1 (en) 2017-08-10
AR105313A1 (es) 2017-09-27
KR20180016972A (ko) 2018-02-20
US10233251B2 (en) 2019-03-19
US20160244528A1 (en) 2016-08-25
US20190161554A1 (en) 2019-05-30
AU2016219772A1 (en) 2017-09-21
CN107921104A (zh) 2018-04-17
JP2018508509A (ja) 2018-03-29
US11180568B2 (en) 2021-11-23
EP3258959A4 (en) 2018-10-17
CA2977257A1 (en) 2016-08-25
US20220025064A1 (en) 2022-01-27
EP3258959A1 (en) 2017-12-27
US10259881B2 (en) 2019-04-16
MX2017010793A (es) 2018-07-06
TW201632559A (zh) 2016-09-16
WO2016134358A1 (en) 2016-08-25

Similar Documents

Publication Publication Date Title
IL284336B (en) Treatment using antibodies that bind to ctla4
IL254088A0 (en) Cure using cd137 binding antibody
IL254260A0 (en) A healing antibody that binds tim3
EP3325009A4 (en) Antibody therapeutics that bind lag3
EP3280443A4 (en) Antibody therapeutics that bind cd38
EP3265125A4 (en) Antibody therapeutics that bind cd47
IL256846A (en) antibody molecules that bind cd22
SG10201912570UA (en) Anti-garp antibody
IL268889A (en) Anti-EPHA4 antibody
GB201508180D0 (en) Antibodies
IL254310A0 (en) A healing antibody that binds psma
GB201515351D0 (en) Antibody
EP3280442A4 (en) Antibody therapeutics that bind cd123
GB201600871D0 (en) Antibody
SI3336185T1 (sl) Protitelo
IL257368A (en) antibody
EP3131580A4 (en) Antibody therapeutics that bind cd147
GB201509907D0 (en) Antibodies
IL254356A0 (en) healing antibody that binds jag1
GB201503438D0 (en) Antibodies
HK1236805A1 (en) Antibody therapeutics that bind cd147
GB201513447D0 (en) Antibody
GB201515570D0 (en) Anti-LAG-3 antibodies
GB201514425D0 (en) Antibodies
GB201508437D0 (en) Antibodies